Giftify (GIFT) announced a significant increase in gift card sales following its announcement of a smart savings program for GLP-1 diabetes and ...

Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among ...

Three U.S. senators are calling on Robert Kennedy Jr. to disclose what he and President Trump discussed with drugmakers ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Record Inventory Increase Meets Growing Consumer Demand for Healthcare Cost-Saving Solutions Surge Driven by Ozempic and Zepbound Prescription Savings Opportunities Combined with Seasonal Health ...

Novo Nordisk announced launching a direct-to-patient online pharmacy NovoCare, offering a more than half-price cut for its ...

Senators ask if contracts between drugmakers and telehealth companies violate the federal anti-kickback statute.

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Lilly makes tirzepatide ... and that has kept them flying off pharmacy shelves. On top of this, analysts expect the weight loss drug market to soar from today's levels. Morgan Stanley predicts ...

The top 10 projected best-selling medications in 2026, including GLP-1 drugs and AbbVie's Skyrizi, have expected global sales reaching up to $31 billiion.

Lilly may face more competitors down the road ... and that has kept them flying off pharmacy shelves. On top of this, analysts expect the weight loss drug market to soar from today's levels.